Table 1.
Characteristics of patients at TT, including lymphodepletion and CAR T-cell infusion according to relapse
| Nonrelapse (n = 61) | Relapse (n = 55) | HR (95% CI) | P | |
|---|---|---|---|---|
| Age ≥65 y | 24 (39) | 18 (33) | 0.74 (0.41 -1.33) | .24 |
| Males | 36 (59) | 39 (71) | 1.79 (0.97-3.29) | .06 |
| Lymphoma | ||||
| DLBCL | 44 (72) | 49 (89) | 1.00 | |
| PMBL | 3 (5) | 3 (6) | 0.92 (0.28-2.96) | .89 |
| Transformed FL | 14 (23) | 3 (5) | 0.34 (0.11-1.10) | .07 |
| BCL2 expression >70%, n | 14 | 5 | 0.60 (0.23-1.53) | .29 |
| MYC expression, n | ||||
| >40% | 10 | 11 | 1.07 (0.43-2.66) | .88 |
| >80% | 2 | 6 | 1.82 (0.66-5.08) | .25 |
| Missing data | 42 | 34 | ||
| Primary refractory | 42 (64) | 35 (70) | 1.19 (0.42-3.35) | .74 |
| Prior lines (IQR), n | 3 (2-4) | 3 (2-4) | 0.99 (0.82-1.18) | .89 |
| Prior lines ≥4 | 18 (29) | 16 (29) | 1.06 (0.59-1.90) | .85 |
| Prior autograft | 18 (29) | 15 (27) | 0.84 (0.46-1.52) | .56 |
| ECOG PS | ||||
| 0 | 30 (49) | 20 (36) | 1.00 | |
| 1 | 27 (44) | 25 (45) | 1.37 (0.77-2.44) | .28 |
| 2 | 4 (7) | 10 (18) | 2.05 (0.87-4.84) | 0.10 |
| Ann Arbor | ||||
| Stage 0-I-II | 20 (33) | 7 (13 | ||
| Stage III | 6 (10) | 7 (13) | 1.00 | |
| Stage IV | 35 (57) | 41 (75) | 1.96 (1.05-3.66) | .034 |
| EN sites (IQR), n | 1 (0-1) | 1 (1-2) | 1.54 (1.26-1.90) | <.0001 |
| EN sites ≥2 | 10 (16) | 23 (42) | ||
| Elevated LDH at day 0 | 21 (34) | 34 (62) | 4.03 (2.34-6.94) | <.0001 |
| IPI | ||||
| Low IPI | 24 (39) | 12 (22) | 0.21 (0.09-0.49) | <.0001 |
| Low-intermediate IPI | 20 (33) | 15 (27) | 0.28 (0.13-0.63) | .002 |
| High-intermediate IPI | 13 (21) | 15 (27) | 0.51 (0.24-1.10) | .086 |
| High IPI | 4 (6) | 13 (24) | 1.00 | |
| R-IPI | ||||
| Very good R-IPI | 8 (13) | 2 (4) | 0.25 (0.03-1.88) | .18 |
| Good R-IPI | 36 (59) | 25 (45) | 1.00 | |
| Poor R-IPI | 17 (28) | 28 (51) | 2.91 (1.66-5.11) | .0002 |
| CRP at day 0 >30 mg/L | 8 (13) | 29 (57) | 5.57 (3.10-10.0) | <.0001 |
| Bulky mass >5 cm | 20 (33) | 34 (62) | 2.83 (1.62-4.93) | .0003 |
| Bulky mass >10 cm | 5 (8) | 10 (18) | 1.80 (0.87-3.68) | .11 |
| Time between enrollment and apheresis (IQR), d | 10 (7-18) | 7 (3.5-13.5) | 1.00 (0.99-1.01) | .83 |
| Time between apheresis and delivery (IQR), d | 31 (29-34) | 35 (29-38) | 1.00 (0.98-1.01) | .58 |
| Time between delivery and infusion (IQR), d | 7 (6-8.5) | 7 (5-8) | 1.00 (0.95-1.04) | .72 |
| CAR T-cell | .005 | |||
| Kymriah | 16 (26) | 33 (60) | 1.00 | |
| Yescarta | 45 (74) | 22 (40) | 0.47 (0.27-0.60) | |
| Bridging therapy | 47 (77) | 54 (98) | 10.2 (1.42-74.1) | .021 |
| Type of bridging therapy | .006 | |||
| High | 35 (57) | 43 (78) | 1.00 | |
| Low | 26 (43) | 12 (22) | 0.39 (0.20-0.76) | |
| Cycles during bridging therapy, median (range), n | 1.5 (1-2) | 2 (2-3) | 1.51 (1.20-1.91) | .0005 |
| Status at infusion | ||||
| Partial response | 12 (20) | 10 (18) | 1.00 | |
| Stable disease | 16 (26) | 2 (4) | 0.26 (0.06-1.24) | .092 |
| Progressive disease | 33 (54) | 43 (78) | 1.98 (0.93-4.22) | .076 |
Unless otherwise noted, data are n (%). TT includes lymphodepletion and CAR T-cell infusion.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; R-IPI, revised IPI.